Sign In
Buy XBI
$129.83
+2.07 (+1.62%)
At Close: Jun 03, 2026
3 Biotech Stocks to Buy on the Dip: March 2024
01:07pm, Wednesday, 27'th Mar 2024
One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
07:20am, Monday, 25'th Mar 2024
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched
XBI: Biotech Is A Strong Buy As M&A Activity Picks Up (Rating Upgrade)
04:50am, Wednesday, 20'th Mar 2024
Shares of biotechnology companies have been lagging behind the S&P 500 Index. This underperformance of XBI relative to the S&P 500, however, has only made the opportunity even more attractive to us. E
3 Biotech ETFs Overdue for a Bounce
02:45pm, Tuesday, 19'th Mar 2024
Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of c
Mizuho's Jared Holz on finding opportunities in the biotech space
02:25pm, Wednesday, 06'th Mar 2024
Jared Holz, Mizuho Securities America healthcare equity strategist, joins 'The Exchange' to discuss why he believes we are in the midst of the most pronounced biotech rally in over five years, whether
Here's why SPDR Biotech ETF (XBI) stock price is flying
01:05am, Wednesday, 28'th Feb 2024
The SPDR Biotech ETF (XBI) stock has surged hard in the past few weeks as investors cheer the recent FDA approvals and M&A activity in the industry. It has soared in the past four straight weeks and i
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
07:21am, Thursday, 22'nd Feb 2024
The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Navigating the big run in biotech
01:44pm, Thursday, 15'th Feb 2024
The 'Halftime Report' Investment Committee debates the upside potential in the biotech space.
Where Are Biotech ETFs Headed After Q4 Earnings?
05:51pm, Wednesday, 14'th Feb 2024
Look into how Biotech ETFs performed after Q4 earnings.
Biopharmaceutical Stocks: The Next Leg Of The Rally May Begin Soon
11:48pm, Tuesday, 13'th Feb 2024
The thirty-month bear market in biopharmaceutical stocks ended last October. The subsequent rally was standard, beginning with acquisitions at generous premiums.
THQ Vs. XBI: Keeping The Biotech ETF For Now
01:00am, Sunday, 28'th Jan 2024
The U.S. Healthcare sector has shown strong growth and is projected to continue growing due to the increasing number of Americans entering Medicare. The SPDR S&P Biotech ETF invests in biotech and pha
XBI: Biotech Speculation
06:10pm, Tuesday, 23'rd Jan 2024
The SPDR S&P Biotech ETF performance is more dependent on M&A than fundamental growth. The ETF has outperformed the NASDAQ since its inception but has seen a sharp decline since 2021 due to the end of
Healthcare In 2024: Navigating The Biopharma Bull Run
11:22pm, Wednesday, 17'th Jan 2024
The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to
5 Closed-End Fund Buys In The Month Of December 2023 (Plus 1 Sell)
05:02am, Tuesday, 16'th Jan 2024
Equity and fixed-income markets had another strong month in December, driven by continuing retreating risk-free Treasury rates. We even saw an improvement in the breadth of the overall market, with br
Biotech ETFs Stage Solid Comeback at the Start of 2024
12:47pm, Tuesday, 09'th Jan 2024
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-
